Opportunities to enhance antibiotic stewardship: colistin use and outcomes in a low-resource setting
- PMID: 34806008
- PMCID: PMC8599735
- DOI: 10.1093/jacamr/dlab169
Opportunities to enhance antibiotic stewardship: colistin use and outcomes in a low-resource setting
Abstract
Background: Colistin use is increasing with the rise in MDR Gram-negative infections globally. Effective antibiotic stewardship is essential to preserve this antibiotic of last resort.
Objectives: This study investigated stewardship and safety errors related to colistin use to identify opportunities for improvement.
Patients and methods: A prospective descriptive study involving all patients 13 years and older treated with colistin at a tertiary hospital in Cape Town, South Africa, between August 2018 and June 2019. We collected clinical, laboratory and outcome data and assessed provided treatment for stewardship and safety errors.
Results: We included 44 patients. Treatment errors were identified for 34 (77%) patients (median = 1), most commonly inadequate monitoring of renal function (N = 16, 32%). We also identified no rational indication for colistin (N = 9, 20%), loading dose error (N = 12, 27%); maintenance dose error (N = 10, 23%); no prior culture (N = 11, 25%); and failure to de-escalate (2 of 9) or adjust dose to changes in renal function (6 of 15). All cause in-hospital mortality was 47%. Amongst survivors, median ICU stay was 6 days and hospital stay more than 30 days. Eight (18%) patients developed renal injury or failure during treatment. Three (7%) patients in this study were found to have colistin-resistant organisms including two prior to colistin exposure.
Conclusions: This study has identified opportunities to enhance colistin stewardship and improve efficacy and safety of prescription. The appearance of colistin-resistant organisms reinforces the urgent need to ensure effective and appropriate use of colistin.
© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
Figures


Similar articles
-
Opportunities to optimise colistin stewardship in hospitalised patients in South Africa: Results of a multisite utilisation audit.S Afr Med J. 2017 Dec 13;108(1):28-32. doi: 10.7196/SAMJ.2017.v108i1.12561. S Afr Med J. 2017. PMID: 29262975
-
Reinforcement of an antimicrobial stewardship task force aims at a better use of antibiotics of last resort: the COLITIFOS study.Int J Antimicrob Agents. 2017 Aug;50(2):142-147. doi: 10.1016/j.ijantimicag.2017.03.030. Epub 2017 Jul 8. Int J Antimicrob Agents. 2017. PMID: 28694232
-
A retrospective review of colistin utilisation at a tertiary care academic hospital in South Africa.S Afr J Infect Dis. 2021 Jun 18;36(1):205. doi: 10.4102/sajid.v36i1.205. eCollection 2021. S Afr J Infect Dis. 2021. PMID: 34485491 Free PMC article.
-
Emerging infections in burns.Surg Infect (Larchmt). 2009 Oct;10(5):389-97. doi: 10.1089/sur.2009.024. Surg Infect (Larchmt). 2009. PMID: 19810827 Free PMC article. Review.
-
Resistance to Colistin in Klebsiella Pneumoniae: A 4.0 Strain?Infect Dis Rep. 2017 May 31;9(2):7104. doi: 10.4081/idr.2017.7104. eCollection 2017 May 31. Infect Dis Rep. 2017. PMID: 28626539 Free PMC article. Review.
Cited by
-
Antibiotic Use and Stewardship Indicators in the First- and Second-Level Hospitals in Zambia: Findings and Implications for the Future.Antibiotics (Basel). 2022 Nov 15;11(11):1626. doi: 10.3390/antibiotics11111626. Antibiotics (Basel). 2022. PMID: 36421270 Free PMC article.
-
Pre- and Post-COVID-19 Antibiotic Consumption and Stewardship Program in a Southern Italian Hospital.Antibiotics (Basel). 2024 Nov 24;13(12):1128. doi: 10.3390/antibiotics13121128. Antibiotics (Basel). 2024. PMID: 39766518 Free PMC article.
-
Ongoing Efforts to Improve Antimicrobial Utilization in Hospitals among African Countries and Implications for the Future.Antibiotics (Basel). 2022 Dec 15;11(12):1824. doi: 10.3390/antibiotics11121824. Antibiotics (Basel). 2022. PMID: 36551481 Free PMC article.
-
Prevalence, Appropriateness, and Outcomes of Colistin Use in Multidrug-Resistant Pseudomonas aeruginosa Infections: Insights from Hospital Data.Medicina (Kaunas). 2025 Jul 15;61(7):1275. doi: 10.3390/medicina61071275. Medicina (Kaunas). 2025. PMID: 40731904 Free PMC article.
-
The impact of colistin-based regimens on mortality compared to other antimicrobials in patients with carbapenem-resistant Enterobacterales bacteremia in South African hospitals: a cross-sectional study.BMC Infect Dis. 2024 Jun 5;24(1):561. doi: 10.1186/s12879-024-09459-x. BMC Infect Dis. 2024. PMID: 38840122 Free PMC article.
References
-
- Biswas S, Brunel JM, Dubus JC. et al. Colistin: an update on the antibiotic of the 21st century. Expert Rev Anti Infect Ther 2012; 10: 917–34. - PubMed
-
- Kanj SS, Kanafani ZA.. Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum β-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc 2011; 86: 250–9. - PMC - PubMed
-
- Bamford C, Bonorchis K, Elliott E. et al. Antimicrobial susceptibility patterns of selected bacteraemic isolates from public sector hospitals in South Africa. S Afr J Epidemiol Infect 2009; 24: 28–30.
-
- Visser Kift E, Maartens G, Bamford C.. Systematic review of the evidence for rational dosing of colistin. S Afr Med J 2014; 104: 183–6. - PubMed
-
- WHO. Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery and Development of New Antibiotics. https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-E....
LinkOut - more resources
Full Text Sources